ARTICLE | Clinical News
LibiGel testosterone: Interim Phase III data
October 25, 2010 7:00 AM UTC
Interim data from about 2,300 evaluable women in a double-blind, placebo-controlled, international Phase III safety trial evaluating transdermal LibiGel for 12 months showed that the rates of cardiova...